Why FIH oncology trials fail before they start
A perspective on site mix, protocol assumptions, activation delays, and hidden execution risk.
Insights
Signals worth reviewing before early oncology execution.
A practical resource page for public research, oncology conference signals, and our perspective on FIH execution risk. Public Apex AI articles and official sources such as ASCO, ESMO, AACR, and SITC are available as filterable source material with original links preserved.
Featured perspectives
Start with the questions sponsors usually discover too late.
These short editorial themes give the Insights page a stable point of view even when external public-source feeds are temporarily unavailable.
Site-level activation risk vs traditional feasibility
Why averages and prestige-based KOL selection can miss the operational tails that matter.
China innovation drugs going global
How global development strategy, region selection, and trial design affect credibility outside China.
How oncology site selection should differ by mechanism
Why ADCs, bispecifics, KRAS, CAR-T, radioligands, DDR assets, and TKIs should not use the same site logic.
Article library
Public research and oncology conference signals
A unified library of public Apex AI articles and official oncology meeting sources such as ASCO, ESMO, AACR, and SITC. Filter by source, topic, or keyword; cards preserve public metadata and official source links only.
Source: Apex AI articles · Topic: AI · 5 articles · 10 per page
AI at ASCO 2026: From Topic to Tool
AI tags 220 abstracts, the largest subtrack at ASCO 2026. Most of it is applied to concrete tasks; trial matching is where it meets drug development most directly.
Open AAI article
AUA 2026 mPC — Five Trends: Triplet Gradient, PSMA-PET, PSMAddition, Survivorship, AI Gap
Reading 50 advanced and metastatic prostate-cancer abstracts at AUA 2026: triplet gradient, PSMA-PET reclassification, PSMAddition, survivorship-as-section, and what is still missing.
Open AAI articleAUA 2026 — AI and Robots Are Both Here. They Haven't Met Yet.
621 abstracts, one in five. Single-port leads, LLMs arrive, and the AI-robot intersection is nearly empty.
Open AAI articleAACR 2026 — Head and Neck Cancer Gets a New Pipeline
358 HNSCC abstracts, new therapeutic architectures, diversifying biomarkers, and three bets against checkpoint-refractory disease.
Open AAI articleAACR 2026 — Where AI Showed Up in Cancer Research
Reading 7,066 abstracts to map where AI is the default tool, and where the white space still is.
Open AAI article